41 related articles for article (PubMed ID: 17638901)
1. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist.
Ayers M; Fargnoli J; Lewin A; Wu Q; Platero JS
Cancer Res; 2007 Jul; 67(14):6899-906. PubMed ID: 17638901
[TBL] [Abstract][Full Text] [Related]
2. Role of CD93 in Health and Disease.
Tossetta G; Piani F; Borghi C; Marzioni D
Cells; 2023 Jul; 12(13):. PubMed ID: 37443812
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of an inflammation-related lncRNAs signature for improving outcomes of patients in colorectal cancer.
Huang M; Ye Y; Chen Y; Zhu J; Xu L; Cheng W; Lu X; Yan F
Front Genet; 2022; 13():955240. PubMed ID: 36246600
[No Abstract] [Full Text] [Related]
4. C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation.
Khan KA; McMurray JL; Mohammed F; Bicknell R
FEBS J; 2019 Sep; 286(17):3299-3332. PubMed ID: 31287944
[TBL] [Abstract][Full Text] [Related]
5. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
Chan JK; Deng W; Higgins RV; Tewari KS; Bonebrake AJ; Hicks M; Gaillard S; Ramirez PT; Chafe W; Monk BJ; Aghajanian C
Gynecol Oncol; 2017 Sep; 146(3):554-559. PubMed ID: 28728751
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic platinum through glycan targeting.
Peterson EJ; Daniel AG; Katner SJ; Bohlmann L; Chang CW; Bezos A; Parish CR; von Itzstein M; Berners-Price SJ; Farrell NP
Chem Sci; 2017 Jan; 8(1):241-252. PubMed ID: 28451171
[TBL] [Abstract][Full Text] [Related]
7. New advances in targeted gastric cancer treatment.
Lazăr DC; Tăban S; Cornianu M; Faur A; Goldiş A
World J Gastroenterol; 2016 Aug; 22(30):6776-99. PubMed ID: 27570417
[TBL] [Abstract][Full Text] [Related]
8. Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.
Akl MR; Nagpal P; Ayoub NM; Tai B; Prabhu SA; Capac CM; Gliksman M; Goy A; Suh KS
Oncotarget; 2016 Jul; 7(28):44735-44762. PubMed ID: 27007053
[TBL] [Abstract][Full Text] [Related]
9. Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma.
Raoul JL; Park JW; Kang YK; Finn RS; Kim JS; Yeo W; Polite BN; Chao Y; Walters I; Baudelet C; Lencioni R
Liver Cancer; 2014 Oct; 3(3-4):439-50. PubMed ID: 26280005
[TBL] [Abstract][Full Text] [Related]
10. Zerumbone, Sesquiterpene Photochemical from Ginger, Inhibits Angiogenesis.
Park JH; Park GM; Kim JK
Korean J Physiol Pharmacol; 2015 Jul; 19(4):335-40. PubMed ID: 26170737
[TBL] [Abstract][Full Text] [Related]
11. BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth.
Wang T; Xiao M; Ge Y; Krepler C; Belser E; Lopez-Coral A; Xu X; Zhang G; Azuma R; Liu Q; Liu R; Li L; Amaravadi RK; Xu W; Karakousis G; Gangadhar TC; Schuchter LM; Lieu M; Khare S; Halloran MB; Herlyn M; Kaufman RE
Clin Cancer Res; 2015 Apr; 21(7):1652-64. PubMed ID: 25617424
[TBL] [Abstract][Full Text] [Related]
12. Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.
Nakamura I; Zakharia K; Banini BA; Mikhail DS; Kim TH; Yang JD; Moser CD; Shaleh HM; Thornburgh SR; Walters I; Roberts LR
PLoS One; 2014; 9(4):e92273. PubMed ID: 24710173
[TBL] [Abstract][Full Text] [Related]
13. FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma.
Brunello E; Brunelli M; Bogina G; Caliò A; Manfrin E; Nottegar A; Vergine M; Molino A; Bria E; Massari F; Tortora G; Cingarlini S; Pedron S; Chilosi M; Zamboni G; Miller K; Martignoni G; Bonetti F
J Exp Clin Cancer Res; 2012 Dec; 31(1):103. PubMed ID: 23270564
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor receptor 2: expression, roles, and potential as a novel molecular target for colorectal cancer.
Matsuda Y; Ueda J; Ishiwata T
Patholog Res Int; 2012; 2012():574768. PubMed ID: 22701813
[TBL] [Abstract][Full Text] [Related]
15. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
Allen E; Walters IB; Hanahan D
Clin Cancer Res; 2011 Aug; 17(16):5299-310. PubMed ID: 21622725
[TBL] [Abstract][Full Text] [Related]
16. Preclinical development of molecular-targeted agents for cancer.
Ocana A; Pandiella A; Siu LL; Tannock IF
Nat Rev Clin Oncol; 2010 Dec; 8(4):200-9. PubMed ID: 21135887
[TBL] [Abstract][Full Text] [Related]
17. Personalized therapies in the cancer "omics" era.
Ocaña A; Pandiella A
Mol Cancer; 2010 Jul; 9():202. PubMed ID: 20670437
[TBL] [Abstract][Full Text] [Related]
18. An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types.
Staub E; Groene J; Heinze M; Mennerich D; Roepcke S; Klaman I; Hinzmann B; Castanos-Velez E; Pilarsky C; Mann B; Brümmendorf T; Weber B; Buhr HJ; Rosenthal A
J Mol Med (Berl); 2009 Jun; 87(6):633-44. PubMed ID: 19399471
[TBL] [Abstract][Full Text] [Related]
19. Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening.
Peach ML; Tan N; Choyke SJ; Giubellino A; Athauda G; Burke TR; Nicklaus MC; Bottaro DP
J Med Chem; 2009 Feb; 52(4):943-51. PubMed ID: 19199650
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
